E-7050_928037-13-2_DataSheet_MedChemExpress
Diva Decloaker 10X Pretreatment Reagent 说明书
Intended Use:For In Vitro Diagnostic UseHeat induced antigen retrieval of formalin-fixed paraffin-embedded (FFPE) tissues for immunohistochemistry (IHC) procedures. The clinical interpretation of any staining or its absence should be complimented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.Summary & Explanation:Diva Decloaker is a heat retrieval solution that is compatible with virtually all antibodies and eliminates the need for multiple buffers including citrate buffer, EDTA or high pH tris buffers. Antibody titers are doubled and tripled when compared to citrate buffer, pH 6.0. Diva Decloaker incorporates Assure™ tech nology, a color-coded high temperatures pH indicator solution. The end-user is assured by visual inspection that the solution is at the correct dilution and pH. This product is specially formulated for superior pH stability at high temperatures and will help prevent the possibility of losing pH sensitive antigens. Diva Decloaker is non-toxic, non-flammable, odorless and sodium azide and thimerosal free.Known Applications:Immunohistochemistry (formalin-fixed paraffin-embedded tissues) Supplied As:100mlDiva Decloaker, 10X concentrate (DV2004LX)500mlDiva Decloaker, 10X concentrate (DV2004MX)Materials and Reagents (Needed But Not Provided): Microscope slides, positively chargedDesert Chamber* (Drying oven)Positive and negative tissue controlsXylene (Could be substituted with xylene substitute*)Ethanol or reagent alcoholDecloaking Chamber* (Pressure cooker)Deionized or distilled waterWash buffer*(TBS/PBS)Enzyme digestion*Avidin-Biotin Blocking Kit*(Labeled Streptavidin Kits Only) Peroxidase block*Protein block*Primary antibody*Negative control reagents*Detection kits*Detection components*Chromogens*Hematoxylin*Bluing reagent*Mounting medium** Biocare Medical Products: Refer to a Biocare Medical catalog for further information regarding catalog number and ordering information. Certain reagents listed above are based on specific application and detection system used. Storage and Stability:Store at room temperature. Do not use after expiration date printed on vial. If reagents are stored under conditions other than those specified in the package insert, they must be verified by the user. Diluted reagents should be used promptly; any remaining reagent should be stored at room temperature.Protocol Recommendations:1. Deparaffinize tissues and hydrate to water. If necessary, block for endogenous peroxidase and wash in DI water.2. Dilute concentrated Diva Decloaker at a ratio of 1:10 (1 ml Diva to 9 ml of deionized water).3. Place slides into 1X retrieval solution in a slide container (e.g. Coplin Jar, Tissue -Tek™ staining dish or metal slide canister).4. Retrieve sections under pressure using Biocare's Decloaking Chamber. Follow the recommendations on the antibody data sheet and Decloaking Chamber User Manual.5. Check solution for appropriate color change. (See Technical Note #1)6. Gently rinse by gradually adding DI water to the solution, then remove slides and rinse with DI water.Technical Notes:1. Concentrated Diva Decloaker is a bright yellow color. RTU or 1X solution is a pale yellow color. When the solution reaches 80-125°C, the solution turns yellow and indicates that the high temperature solution is at correct pH. Should the pH rise above 7.0, the solution turns a fuschia red color. Should the pH drop too low, thesolution turns a pink color.2. If using Biocare’s Desert Chamber Pro (a programmable turbo-action drying oven), dry sections at 25ºC overnight or at 37ºC for 30-60 minutes and then dry slides at 60ºC for 30 minutes.3. Use positive char ged slides (use Biocare’s Kling-On HIER Slides) and cut tissues at 4-5 microns. Do not use any adhesives in the water bath. Poor fixation and processing of tissues will cause tissue sections to fall off the slides, especially fatty tissues such as breast. Tissues should be fixed a minimum of 6-12 hours.4. Protocol time and temperatures for HIER can vary depending on the Decloaking Chamber model used. Please refer to the relevant Decloaking Chamber manual for appropriate protocol times and temperatures.Limitations:The protocols for a specific application can vary. These include, but are not limited to: fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, asresults may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions. The clinical interpretation of any positive or negative staining should be evaluated within the context of clinical presentation, morphology and other histopathological criteria by a qualified pathologist. The clinical interpretation of any positive or negative staining should be complemented by morphological studies using proper positive and negative internal and external controls as well as other diagnostic tests.Catalog Number: DV2004 LX, MX Description: 100, 500 ml, concentrateQuality Control:Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2). CLSI Wayne, PA, USA (). 2011 Precautions:1. This product is not classified as hazardous. The preservative used in this reagent is Proclin 300 and the concentration is less than 0.25%. Overexposure to Proclin 300 can cause skin and eye irritation and irritation to mucous membranes and upper respiratory tract. The concentration of Proclin 300 in this product does not meet the OSHA criteria for a hazardous substance. Wear disposable gloves when handling reagents.2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come in contact with sensitive areas, wash with copious amounts of water.3. Microbial contamination of reagents may result in an increase in nonspecific staining.4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.5. Do not use reagent after the expiration date printed on the vial.6. The SDS is available upon request and is located at /.7. Consult OSHA, federal, state or local regulations for disposal of any toxic substances. Proclin is a trademark of Rohm and Haas Company, or of its subsidiaries or affiliates.Troubleshooting:Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.。
XMD8-87_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:XMD8–87 is a potent TNK2 inhibitor with IC 50 values of 38 and 113 nM for the D163E and R806Q mutations, respectively.IC50 & Target: IC50: 38 nM (TNK2, D163E mutation), 113 nM (TNK2, R806Q mutation)[1]In Vitro: XMD8–87 potently inhibits the growth of the TNK2 mutant expressing cell lines while having little or no effect on the control cells out to the highest tested concentrations (1,000 nM). XMD8–87 has IC 50s of 38 nM and 113 nM for the D163E and R806Q mutations. The effects of XMD8–87 on TNK2 cell lines are largely due to on–target effects on TNK2. Auto–phosphorylation of overexpressed TNK2 mutants could be blocked with TNK2 inhibitor XMD8–87[1].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]Kinase targets are tested with biochemical enzymatic kinase assays using the SelectScreen Kinase Profiling Service to determine IC 50 values. The compounds (XMD8–87) are assayed at 10 concentrations (3–fold serial dilutions starting from 1 μM) at an ATP concentration equal to the ATP Km [1].Cell Assay:[1]Cells are treated with the following inhibitors for 72 hours: dasatinib, AIM–100, XMD8–87 and XMD16–5. Cell viability is measured using a methanethiosulfonate (MTS)–based assay and absorbance (490 nm) is read at 1 and 3 hours after adding reagent [1].References:[1]. Maxson JE, et al. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.Product Name:XMD8–87Cat. No.:HY-15811CAS No.:1234480-46-6Molecular Formula:C 24H 27N 7O 2Molecular Weight:445.52Target:Tyrosinase Pathway:Metabolic Enzyme/Protease Solubility:DMSO: ≥ 26 mg/mLCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
超声波手术机器人获FDA突破性设备认定
超声波手术机器人获FDA突破性设备认定
无
【期刊名称】《中国医学计算机成像杂志》
【年(卷),期】2024(30)2
【摘要】2024年3月4日,机器人超声治疗领域全球领导企业EDAPTMSSA(纳斯达克股票代码:EDAP)宣布,其FocalOne高强度聚焦超声(HIFU)平台已获得美国食品和药品监督管理局(FDA)的“突破性设备”认定,用于治疗深部浸润型子宫内膜异位症(DIE)。
2018年6月,FDA已批准Focal One机器人用于前列腺组织消融。
【总页数】1页(P249-249)
【作者】无
【作者单位】思宇MedTech
【正文语种】中文
【中图分类】R73
【相关文献】
1.TNX-102 SL用于创伤后应激障碍治疗获FDA突破性疗法认定
2.Apabetalone(RVX-208)获美国FDA突破性疗法认定
3.中国自主研发抗癌新药首获FDA突破性疗法认定
4.多发性硬化症药治疗奥瑞珠单抗获FDA突破性疗法认定
tozinemab获FDA突破性疗法认定,治疗痴呆症
因版权原因，仅展示原文概要，查看原文内容请购买。
PCR试剂盒类型
微生物检测试剂盒项目核酸 种类产品编号 产品名称方 法规 格 价 格沙门氏菌 DNASA-6131 沙门氏菌(Spp)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-6132 沙门氏菌(Spp)核酸检测试剂盒 常规PCR40份/盒2000 副溶血性弧菌 DNASA-7051副溶血性弧菌(VP)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7052副溶血性弧菌(VP)核酸检测试剂盒 常规PCR40份/盒2000 霍乱弧菌 DNASA-7061 霍乱弧菌(VC)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7062 霍乱弧菌(VC)核酸检测试剂盒 常规PCR40份/盒2000 大肠杆菌 DNASA-7071大肠杆菌(O157:H7)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7072大肠杆菌(O157:H7)核酸检测试剂盒常规PCR40份/盒2000 单增李斯特菌 DNASA-7081单增李斯特菌(LM)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7082单增李斯特菌(LM)核酸检测试剂盒常规PCR40份/盒2000 金黄色葡萄球菌 DNASA-7091金黄色葡萄球菌(MRSA)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7092金黄色葡萄球菌(MRSA)核酸检测试剂盒常规PCR40份/盒2000 口腔变形链球菌 DNASA-7111口腔变形链球菌(SM)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7112口腔变形链球菌(SM)核酸检测试剂盒常规PCR40份/盒2000 幽门螺旋杆菌 DNASA-7121幽门螺旋杆菌(HP)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7122幽门螺旋杆菌(HP)核酸检测试剂盒 常规PCR40份/盒2000 乳酸杆菌 DNASA-7131 乳酸杆菌(LB)核酸检测试剂盒PCR-荧光探针法 40份/盒2400 SA-7132 乳酸杆菌(LB)核酸检测试剂盒 常规PCR40份/盒2000 双歧杆菌 DNASA-7141 双歧杆菌(BD)核酸检测试剂盒PCR-荧光探针法 40份/盒 2400 SA-7142 双歧杆菌(BD)核酸检测试剂盒常规PCR 40份/2000盒嗜肺军团杆菌 DNASA-7151 嗜肺军团杆菌(LP)核酸检测试剂盒 PCR-荧光探针法 40份/盒2400SA-7152 嗜肺军团杆菌(LP)核酸检测试剂盒 常规PCR 40份/盒2000空肠弯曲菌 DNA SA-7161 空肠弯曲菌(CJ)核酸检测试剂盒 PCR-荧光探针法 40份/盒2400SA-7162 空肠弯曲菌(CJ)核酸检测试剂盒 常规PCR 40份/盒2000甲型副伤寒沙门氏菌 DNASA-7171 甲型副伤寒沙门氏菌(SPA)核酸检测试剂盒 PCR-荧光探针法 40份/盒2400SA-7172 甲型副伤寒沙门氏菌(SPA)核酸检测试剂盒 常规PCR 40份/盒2000动物检测试剂盒项目 核酸 种类产品编号产品名称 方 法 规 格 价格新城疫 RNASA-6091 新城疫病毒(NDV)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6092 新城疫病毒(NDV)核酸检测试剂盒 RT-PCR 法 40头份/盒 28禽流感 RNASA-6011 禽流感病毒通用型(AIV-U)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6012 禽流感病毒通用型(AIV-U)核酸检测试剂盒 RT-PCR 法 40头份/盒 28SA-6013 禽流感病毒H5亚型(AIV-H5N1)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6014 禽流感病毒H5亚型(AIV-H5N1)核酸检测试剂盒 RT-PCR 法 40头份/盒 28SA-6015 禽流感病毒H7亚型(AIV-H7)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 320 SA-6016 禽流感病毒H7亚型(AIV-H7)核酸检测试剂盒 RT-PCR 法 40头份/盒 28SA-6017 禽流感病毒H9亚型(AIV-H9)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6018 禽流感病毒H9亚型(AIV-H9)核酸检测试剂盒 RT-PCR 法 40头份/盒 28SA-6019 禽流感病毒(AIV)基因分型核酸检测试剂盒 多重RT-PCR 法 10头份/盒 16口蹄疫 RNASA-6021 口蹄疫病毒通用型(FMDV-U)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6022 口蹄疫病毒通用型(FMDV-U)核酸检测试剂盒 RT-PCR 法 40头份/盒 28SA-6023 口蹄疫病毒Asia-1�型(FMDV-A1)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6024 口蹄疫病毒Asia-1�型(FMDV-A1)核酸检测试剂盒 RT-PCR 法 40头份/盒 28SA-6025 口蹄疫病毒O �型(FMDV-O)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6026 口蹄疫病毒O �型(FMDV-O)核酸检测试剂盒 RT-PCR 法 40头份/盒 28SA-6027 口蹄疫病毒(FMDV)基因分型核酸检测试剂盒 多重RT-PCR 法 10头份/盒 160 猪蓝耳病 RNASA-6031猪蓝耳病病毒通用型(PRRSV-U)核酸检测试剂盒 PCR-荧光探针法40头份/盒 32SA-6032猪蓝耳病病毒通用型(PRRSV-U)核酸检测试剂盒RT-PCR 法40头份/盒 28SA-6033高致病性猪蓝耳病病毒(PRRSV-M)核酸检测试剂盒 PCR-荧光探针法40头份/盒 32SA-6034高致病性猪蓝耳病病毒(PRRSV-M)核酸检测试剂盒RT-PCR 法40头份/盒 28狂犬病 RNASA-6121 狂犬病毒(RV)核酸检测试剂盒PCR-荧光探针法40头份/盒 32SA-6122 狂犬病毒(RV)核酸检测试剂盒RT-PCR 法40头份/盒 28流行性乙型脑炎RNASA-7011流行性乙型脑炎病毒(JEV)核酸检测试剂盒 PCR-荧光探针法40头份/盒 32SA-7012流行性乙型脑炎病毒(JEV)核酸检测试剂盒RT-PCR 法40头份/盒 28猪瘟 RNASA-6071 猪瘟病毒(CSFV)核酸检测试剂盒PCR-荧光探针法40头份/盒 32SA-6072 猪瘟病毒(CSFV)核酸检测试剂盒RT-PCR 法 40头份/盒 28弓形虫 DNA SA-6051 弓形虫(TOX)核酸检测试剂盒PCR-荧光探针法40头份/盒 240 SA-6052 弓形虫(TOX)核酸检测试剂盒 常规PCR40头份/盒 20布氏杆菌 DNASA-6061 布氏杆菌(BS)核酸检测试剂盒PCR-荧光探针法40头份/盒 24SA-6062 布氏杆菌(BS)核酸检测试剂盒常规PCR40头份/盒 20细小病毒 DNASA-6081 细小病毒(PPV)核酸检测试剂盒PCR-荧光探针法40头份/盒 32SA-6082 细小病毒(PPV)核酸检测试剂盒常规PCR40头份/盒 28伪狂犬 DNASA-6111 伪狂犬病毒(PRV)核酸检测试剂盒PCR-荧光探针法40头份/盒 32SA-6112 伪狂犬病毒(PRV)核酸检测试剂盒常规PCR40头份/盒 28猪疱疹 DNASA-6141 猪疱疹病毒(PHV)核酸检测试剂盒PCR-荧光探针法40头份/盒 24SA-6142 猪疱疹病毒(PHV)核酸检测试剂盒常规PCR40头份/盒 20猪链球菌 DNASA-6041猪链球菌通用型(SS-U)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 24SA-6042猪链球菌通用型(SS-U)核酸检测试剂盒常规PCR40头份/盒 20 SA-6043 猪链球菌Ⅱ型(SS-Ⅱ)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 24SA-6044 猪链球菌Ⅱ型(SS-Ⅱ)核酸检测试剂盒 常规PCR 40头份/盒 2SA-6045 猪链球菌(SS) 基因分型核酸检测试剂盒 多重PCR 10头份/盒 16猪圆环 DNASA-6151 猪圆环病毒(PCV)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 32SA-6152 猪圆环病毒(PCV)核酸检测试剂盒 常规PCR 40头份/盒 28炭疽杆菌 DNASA-6161 炭疽杆菌(BA)核酸检测试剂盒 PCR-荧光探针法 40头份/盒 24SA-6162 炭疽杆菌(BA)核酸检测试剂盒 常规PCR 40头份/盒 20传染病检测试剂盒项目 核酸 种类产品编号产品名称 方 法 规 格 价格艾滋病 RNA SA-2041 人类免疫缺陷(HIV)核酸检测试剂盒 PCR-荧光探针法 40人份/盒 32梅毒 DNA SA-2131 梅毒螺旋体(TP)核酸检测试剂盒 PCR-荧光探针法 40人份/盒 16流感 RNA SA-3051 甲型流感病毒(IAV)核酸检测试剂PCR-荧光探针40人3盒法份/盒 200 SA-3061乙型流感病毒(IBV)核酸检测试剂盒PCR-荧光探针法 40人份/盒 32禽流感 RNA SA-6011禽流感病毒通用型(AIV-U)核酸检测试剂盒PCR-荧光探针法 40人份/盒 32SA-6013禽流感病毒H5亚型(AIV-H5N1)核酸检测试剂盒PCR-荧光探针法 40人份/盒 32SA-6015禽流感病毒H7亚型(AIV-H7)核酸检测试剂盒PCR-荧光探针法 40人份/盒 32SA-6017禽流感病毒H9亚型(AIV-H9)核酸检测试剂盒PCR-荧光探针法 40人份/盒 32SA-6019禽流感病毒(AIV)基因分型核酸检测试剂盒多重RT-PCR 法 10人份/盒 16布氏杆菌 DNASA-6061 布氏杆菌(BS)核酸检测试剂盒PCR-荧光探针法 40人份/盒 24SA-6062 布氏杆菌(BS)核酸检测试剂盒常规PCR 40人份/盒 20狂犬病 RNASA-6121 狂犬病毒(RV)核酸检测试剂盒PCR-荧光探针法 40人份/盒 32SA-6122 狂犬病毒(RV)核酸检测试剂盒RT-PCR 法 40人份/盒 28炭疽 DNA SA-6161 炭疽杆菌(BA)核酸检测试剂盒PCR-荧光探针40人20 0SA-6162 炭疽杆菌(BA)核酸检测试剂盒常规PCR40人份/盒2流行性乙型脑炎RNASA-7011流行性乙型脑炎病毒(JEV)核酸检测试剂盒PCR-荧光探针法40人份/盒320 SA-7012流行性乙型脑炎病毒(JEV)核酸检测试剂盒RT-PCR法40人份/盒28流行性脑脊髓膜炎DNASA-7031脑膜炎奈瑟菌通用型(NM-U)核酸检测试剂盒PCR-荧光探针法40人份/盒240 SA-7032脑膜炎奈瑟菌通用型(NM-U)核酸检测试剂盒常规PCR40人份/盒20 SA-7033脑膜炎奈瑟菌A群(NM-A)核酸检测试剂盒PCR-荧光探针法40人份/盒240 SA-7034脑膜炎奈瑟菌A群(NM-A)核酸检测试剂盒常规PCR40人份/盒20 SA-7035脑膜炎奈瑟菌C群(NM-C)核酸检测试剂盒PCR-荧光探针法40人份/盒240 SA-7036脑膜炎奈瑟菌C群(NM-C)核酸检测试剂盒常规PCR40人份/盒2肺结核DNA SA-3011 结核杆菌(TB)核酸检测试剂盒PCR-荧光探针法40人份/盒16手足口病 RNA SA-7181 肠道病毒EV71核酸检测试剂盒PCR-荧光探针40人300 SA-7182 肠道病毒EV71核酸检测试剂盒 RT-PCR 法40人份/盒 28SA-7185肠道病毒通用型(EV-U)核酸检测试剂盒 PCR-荧光探针法40人份/盒 32SA-7191柯萨奇病毒A16型(CAV-16)核酸检测试剂盒 PCR-荧光探针法40人份/盒 28SA-7192柯萨奇病毒A16型(CAV-16)核酸检测试剂盒RT-PCR 法40人份/盒 32SA-7183肠道病毒EV71/柯萨奇病毒A16型双色荧光检测试剂盒 多重PCR-荧光探针法 40人份/盒 36SA-7187 肠道病毒通用型/肠道病毒EV71/柯萨奇病毒A16型三色荧光检测试剂盒多重PCR-荧光探针法40人份/盒 36登革热 RNASA-7041 登革热病毒(DFV)核酸检测试剂盒PCR-荧光探针法40人份/盒 32SA-7042 登革热病毒(DFV)核酸检测试剂盒 RT-PCR 法40人份/盒 28霍乱 DNASA-7061 霍乱弧菌(VC)核酸检测试剂盒PCR-荧光探针法40人份/盒 24SA-7062 霍乱弧菌(VC)核酸检测试剂盒常规PCR40人份/盒 20临床检测试剂盒产品编号核酸种类 产品名称 方 法规 格 价 格SA-1021 DNA乙型肝炎病毒(HBV)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-2011 DNA 沙眼衣原体(CT)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-2021 DNA 解脲脲原体(UU)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-2031 DNA 淋球菌(NG)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-2061 DNA单纯疱疹病毒通用型(HSV-U)核酸检测试剂盒 PCR-荧光探针法40人份/盒 16SA-2051 DNA单纯疱疹病毒II 型(HSV-II)核酸检测试剂盒 PCR-荧光探针法40人份/盒 16SA-2071 DNA人乳头瘤病毒6,11型(HPV-6,11)核酸检测试剂盒 PCR-荧光探针法40人份/盒 16SA-2081 DNA人乳头瘤病毒16,18型(HPV-16,18)核酸检测试剂盒 PCR-荧光探针法40人份/盒 16SA-2091 DNA人乳头瘤病毒高危型(HR-HPV)核酸检测试剂盒 PCR-荧光探针法40人份/盒 16SA-2101 DNA 人巨细胞病毒(HCMV)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-2111 DNA 白色念珠菌(CA)核酸检测试剂盒PCR-荧光探针法40人份/盒 6SA-2121 DNA生殖道支原体通用型(MG-U)核酸检测试剂盒 PCR-荧光探针法40人份/盒 16SA-2141 DNA 弓形虫(TOX)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-3071 DNA EB 病毒(EBV)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-3021 DNA 肺炎支原体(MP)核酸检测试剂盒PCR-荧光探针法40人份/盒 16SA-A04 DNA 人类白细胞抗原(HLA-B27)核酸检测试剂盒 常规PCR40人份/盒 20SA-1011 RNA 甲型肝炎病毒(HAV)核酸检测试剂盒PCR-荧光探针法40人份/盒 32SA-1031 RNA 丙型肝炎病毒(HCV)核酸检测试剂盒PCR-荧光探针法40人份/盒 32SA-1041 RNA 庚型肝炎病毒(HGV)核酸检测试剂盒PCR-荧光探针法40人份/盒 32SA-3031 RNA 呼吸道合胞病毒(RSV)核酸检测试剂盒PCR-荧光探针法40人份/盒 32SA-5011 RNA 白血病融合基因(Bcr-Abl)核酸检测试剂盒PCR-荧光探针法40人份/盒 32SA-5021 RNA 肿瘤多药耐药基因(MDR1)核酸检测试剂盒PCR-荧光探针法40人份/盒 2SA-A03 RNA肿瘤多药耐药基因(MDR1)甲基化核酸检测试剂盒常规PCR40人份/盒 32SA-5031 RNA肿瘤多药耐药相关蛋白基因(MRP1)核酸检测试剂盒 PCR-荧光探针法 40人份/盒 32科研试剂盒产品编号产品名称方 法规 格 价 格SA-5041 线粒体DNA(mtDNA)核酸检测试剂盒PCR-荧光探针法40份/盒 48SA-5051凋亡抑制蛋白Survivin 基因核酸检测试剂盒 PCR-荧光探针法40份/盒 48SA-5061 凋亡抑制蛋白Livin 基因核酸检测试剂盒PCR-荧光探针法40份/盒 48SA-5071 细胞色素P450核酸检测试剂盒PCR-荧光探针法40份/盒 48SA-5081 血管生长因子VEGF-c 核酸检测试剂盒PCR-荧光探针法40份/盒 48SA-5091 基质金属蛋白酶MMP-2基因核酸检测试剂盒PCR-荧光探针法40份/盒 48SA-5111 黏附分子CD44核酸检测试剂盒PCR-荧光探针法40份/盒 48SA-5121 黏附分子E-cad核酸检测试剂盒PCR-荧光探针法40份/盒8SA-5131 黏附分子ICAM基因核酸检测试剂盒PCR-荧光探针法40份/盒48SA-5141 脊髓延髓肌肉萎缩症(SBMA)核酸检测试剂盒PCR-PAGE法40份/盒48SA-5151 遗传小脑共济失调(SCA) 核酸检测试剂盒PCR-PAGE法10份/盒32SA-5161 注意缺陷多巴胺D4受体基因多态性核酸检测试剂盒PCR-PAGE法40份/盒48SA-5171 注意缺陷多巴胺载脂蛋白基因多态性核酸检测试剂盒PCR-PAGE法40份/盒48SA-5181 Nucleostemin基因核酸检测试剂盒PCR-荧光探针法40份/盒48SA-5191 人Dectin-1基因核酸检测试剂盒PCR-荧光探针法40份/盒48SA-5201 人β,1-3-半乳糖苷酶(β,1-3GT) 基因核酸检测试剂盒PCR-荧光探针法40份/盒48SA-5211 人Cosmc 基因核酸检测试剂盒PCR-荧光探针法40份/盒48SA-5221 雄激素受体AR基因多态性检测试剂盒PCR-STR法40份/盒48SA-5231 CYP17基因多态性检测试剂盒PCR-RLFP法40份/盒8SA-5241 亚基基四氢还原酶基因MTHFR C677T检测试剂盒PCR-RLFP法40份/盒48SA-5251 E-选择素G98T 基因多态性检测试剂盒PCR-RLFP法40份/盒48SA-5261 E-选择素基因S128R基因多态性检测试剂盒PCR-RLFP法40份/盒48SA-5271 细胞间黏附分子-1基因K469E多态性检测试剂盒PCR-RLFP法40份/盒48SA-5281 IL-6基因174G/C多态性检测试剂盒PCR-RLFP法40份/盒48SA-5291 FGFR3 1138G/A多态性检测试剂盒PCR-RLFP法40份/盒48其他相关试剂产品名称产品编号方法/说明规格价格质粒DNA提取试剂盒SA-TQ1101 滤柱法50T/盒350 SA-TQ1102 滤柱法200T/盒12RNA提取试剂盒SA-TQ1201 滤柱法50T/盒950 SA-TQ1202 滤柱法100T/盒18TrizolSA-TQ1301------50ml 480SA-TQ1302------100ml 850RNA 稳定液 SA-TQ1303 ------100ml 800PCR 产物纯化及DNA 凝胶回收试剂盒SA-TQ1401滤柱法50T/盒400 SA-TQ1402滤柱法100T/盒750 基因组DNA 抽提试剂盒SA-TQ1501 滤柱法50T/盒650 SA-TQ1502滤柱法100T/盒 12SA-TQ1601盐析法50T/盒450 SA-TQ1602 盐析法100T/盒800 简易DNA 提取液 SA-TQ1701 ------1ml 100SA-TQ1702 ------5ml 400SA-TQ1703 ------10ml 750淋巴细胞提取液SA-TQ1801------100ml 120SA-TQ1802------250ml 300红细胞裂解液(DNA和蛋白) SA-TQ1901 ------ 100ml15红细胞裂解液(RNA专用) SA-TQ1902 ------ 100ml18100bp MAKER SA-MK1201 ------ 50次180 SA-MK1202 ------ 100次350 SA-MK1203 ------ 200次68DL2000 MAKER SA-MK1701 ------ 50次180 SA-MK1702 ------ 100次350 SA-MK1703 ------ 200次68一步法RT-PCR试剂盒SA-A0101 ------20T/盒80 SA-A0102 ------40T/盒15逆转录试剂盒SA-A0201 ------20T/盒420 SA-A0202 ------40T/盒8Simple PCR Kit（DNA）SA-A0301 ------20T/盒450 SA-A0302 ------40T/盒8Two-Step SYBR GreenER SA765-100 ------ 100次3FQ-RT -PCR Kit 0SA765-500 ------ 500次1 2 0 0 0SYBR GreenER FQ-PCR SuperMix UniversalS SA762-100 ------ 100次150 SA762-500 ------ 500次60 SA762-02K ------2000次198Taq DNA Polymase SA-A0401-01 5U/ul 250U120 SA-A0401-02 5U/ul 500U220 SA-A0401-03 5U/ul 1000U40 SA-A0401-04 5U/ul 5000U18dNTP(10mM each) SA-A0402 ------ 1ml 1 8 02×Taq PCR MIX SA-A0403-01 含红色燃料1ml180 SA-A0403-04 含红色燃料5ml80 SA-A0403-07 含红色燃料10ml 100 2×Taq PCR MIXSA-A0403-02------ 1ml 180SA-A0403-05------ 5ml 800SA-A0403-08------ 10ml 15002×Taq PCR MIXSA-A0403-03定量 1ml 220SA-A0403-06定量 5ml 850SA-A0403-09定量 10ml 1600M-MLV 逆转录酶SA-A0410-01200U/ul 50ul 450SA-A0410-02200U/ul 100ul 800SA-A0410-03200U/ul 200ul 1500Random Primer SA-A0404 50pmol/ul 100ul 810×TE buffer pH8.0SA-A0405 ------ 500ml 350EB 溶液 SA-A0406 ------ 50ul 5EB 清除剂 SA-QT1001 ------ 100ml 68050×TAE BufferSA-A0407------ 50ml 85×TBE Buffer SA-A0408 ------ 200ml 120DEPC 处理水 SA-A0409------100ml 90技术服务项目方法 / 说明 数量 收费标准 总RNA 抽提 根据不同要求收费50例以下80元/例 50例以上 50元/例 总DNA 抽提 根据不同要求收费50例以下50元/例 50例以上 40元/例 荧光定量PCR 不包括引物及探针合成费用50例以下150元/例 50例以上 100元/例 定性PCR MSP-PCR 收费200元/例50例以下100元/例 50例以上 80元/例 PCR-SSCP 不包括测序费用50例以下100元/例 50例以上 80元/例 PCR-RFLP 不包括内切酶的费用50例以下100元/例 50例以上 80元/例 PCR-DHPLC ------50例以下200元/例 50例以上 150元/例 逆转录反应 ------50例以下50元/例 50例以上40元/例 PCR-SSP 不包括试剂盒的费用 ------1000元/ 96T/板载体构建片段如大于500bp，则按1000元/例收费50例以下500元/例50例以上1000元/例DNA测序PCR产物另加10元/个纯化费50例以下80元/例50例以上60元/例ELISA检测不包括试剂盒的费用50例以下1500元/48T/板50例以上2000元/96T/板组织细胞分离培养------ ------ 500元/例Westen blot 最低3500元/张膜 (不包抗体) 50例以下300元/例50例以上200元/例流式细胞仪检测不包抗体等标记50例以下50元/例50例以上30元/例生化检测不包括试剂盒的费用50例以下80元/例50例以上60元/例激光共聚焦检测------ 50例以下500元/例50例以上300元/例外周血淋巴细胞分离Ficoll法50例以下50元/例50例以上40元/例T、B、PBM等细胞分离(磁珠法)50例以下500元/例50例以上400元/例MTT ------ 50例以下1500元/48T/板50例以上2000元/96T/板电镜检测------ 50例以下500元/例50例以上400元/例凋亡检测Tunel法50例以下1500元/48T/板50例以上2000元/48T/板Hoechst 33258染色法50例以下300元/例50例以上250元/例DNA Ladder法50例以下100元/例50例以上80元/例微生物培养分离鉴定不包括试剂盒的费用50例以下100元/例50例以上80元/例微生物药敏实验不包括试剂盒的费用50例以下100元/例50例以上80元/例药物浓度检测------50例以下500元/例50例以上400元/例HPLC法50例以下800元/例50例以上600元/例蛋白质双向电泳------ 50例以下5000元/例50例以上4000元/例蛋白纯化过柱法50例以下500元/例50例以上400元/例HPLC法50例以下800元/例50例以上600元/例蛋白质质谱分析------ 50例以下5000元/例50例以上4000元/例荧光显微镜------ ------ 100元/小时肿瘤药敏实验标本新鲜，最低3000元/例------ 800元/种药物基因芯片分析------ ------ 价格面议核酸诊断试剂盒开发------ ------ 价格面议代理产品产品名称产品编号产地规格价格封闭抗体(APLA) ELISA检测试剂盒SA-FBKT001 原装进口50T/盒80 SA-FBKT002 原装进口100T/盒13ABDR SSP 2x96 TypingKit高通量33200-2.1 美国TBG 40T30 33200-2.2 美国TBG 20T15FK506（普乐可复）药物浓度ELISA检测试剂盒SA-S32400 原装进口96T58封闭抗体分析系统SA-ELX800NB 国产套9 8 0 0 0酶标仪ELX800NB 美国Bio-Tek 台7 8 0 0 0基因扩增仪-48孔*0.2ml(热盖) DTC-3E 国产台48微量荧光检测仪-单孔TL998A 国产套6 8 0 0 0实时荧光定量PCR仪-48孔*0.2ml TL988F 国产套3琼脂糖水平电泳槽DYCP-31E 北京六一厂台2 2 0 0凝胶成像系统WD-9413A 北京六一厂套6 9 0 0 0生物安全柜BSC-1500II A2-X 济南鑫贝西台9 8 0罗氏PCR反应管MB068 国产96/盒3 8 0。
EL-102_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :EL-102Catalog No. :HY-16187CAS No. :1233948-61-21.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:EL 102; EL102Formula:C19H16N2O3S2Molecular Weight:384.47CAS No. :1233948-61-24. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
稳定性英文版
HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationFLUOXETINE HClC17H18F3NO•HClM.W. = 345.79CAS — 59333-67-4STABILITY INDICATINGA S S A Y V A L I D A T I O NMethod is suitable for:ýIn-process controlþProduct ReleaseþStability indicating analysis (Suitability - US/EU Product) CAUTIONFLUOXETINE HYDROCHLORIDE IS A HAZARDOUS CHEMICAL AND SHOULD BE HANDLED ONLY UNDER CONDITIONS SUITABLE FOR HAZARDOUS WORK.IT IS HIGHLY PRESSURE SENSITIVE AND ADEQUATE PRECAUTIONS SHOULD BE TAKEN TO AVOID ANY MECHANICAL FORCE (SUCH AS GRINDING, CRUSHING, ETC.) ON THE POWDER.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationTABLE OF CONTENTS INTRODUCTION........................................................................................................................ PRECISION............................................................................................................................... System Repeatability ................................................................................................................ Method Repeatability................................................................................................................. Intermediate Precision .............................................................................................................. LINEARITY................................................................................................................................ RANGE...................................................................................................................................... ACCURACY............................................................................................................................... Accuracy of Standard Injections................................................................................................ Accuracy of the Drug Product.................................................................................................... VALIDATION OF FLUOXETINE HCl AT LOW CONCENTRATION........................................... Linearity at Low Concentrations................................................................................................. Accuracy of Fluoxetine HCl at Low Concentration..................................................................... System Repeatability................................................................................................................. Quantitation Limit....................................................................................................................... Detection Limit........................................................................................................................... VALIDATION FOR META-FLUOXETINE HCl (POSSIBLE IMPURITIES).................................. Meta-Fluoxetine HCl linearity at 0.05% - 1.0%........................................................................... Detection Limit for Fluoxetine HCl.............................................................................................. Quantitation Limit for Meta Fluoxetine HCl................................................................................ Accuracy for Meta-Fluoxetine HCl ............................................................................................ Method Repeatability for Meta-Fluoxetine HCl........................................................................... Intermediate Precision for Meta-Fluoxetine HCl......................................................................... SPECIFICITY - STABILITY INDICATING EVALUATION OF THE METHOD............................. FORCED DEGRADATION OF FINISHED PRODUCT AND STANDARD..................................1. Unstressed analysis...............................................................................................................2. Acid Hydrolysis stressed analysis..........................................................................................3. Base hydrolysis stressed analysis.........................................................................................4. Oxidation stressed analysis...................................................................................................5. Sunlight stressed analysis.....................................................................................................6. Heat of solution stressed analysis.........................................................................................7. Heat of powder stressed analysis.......................................................................................... System Suitability stressed analysis.......................................................................................... Placebo...................................................................................................................................... STABILITY OF STANDARD AND SAMPLE SOLUTIONS......................................................... Standard Solution...................................................................................................................... Sample Solutions....................................................................................................................... ROBUSTNESS.......................................................................................................................... Extraction................................................................................................................................... Factorial Design......................................................................................................................... CONCLUSION...........................................................................................................................ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationBACKGROUNDTherapeutically, Fluoxetine hydrochloride is a classified as a selective serotonin-reuptake inhibitor. Effectively used for the treatment of various depressions. Fluoxetine hydrochloride has been shown to have comparable efficacy to tricyclic antidepressants but with fewer anticholinergic side effects. The patent expiry becomes effective in 2001 (US). INTRODUCTIONFluoxetine capsules were prepared in two dosage strengths: 10mg and 20mg dosage strengths with the same capsule weight. The formulas are essentially similar and geometrically equivalent with the same ingredients and proportions. Minor changes in non-active proportions account for the change in active ingredient amounts from the 10 and 20 mg strength.The following validation, for the method SI-IAG-206-02 , includes assay and determination of Meta-Fluoxetine by HPLC, is based on the analytical method validation SI-IAG-209-06. Currently the method is the in-house method performed for Stability Studies. The Validation was performed on the 20mg dosage samples, IAG-21-001 and IAG-21-002.In the forced degradation studies, the two placebo samples were also used. PRECISIONSYSTEM REPEATABILITYFive replicate injections of the standard solution at the concentration of 0.4242mg/mL as described in method SI-IAG-206-02 were made and the relative standard deviation (RSD) of the peak areas was calculated.SAMPLE PEAK AREA#15390#25406#35405#45405#55406Average5402.7SD 6.1% RSD0.1ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::PRECISION - Method RepeatabilityThe full HPLC method as described in SI-IAG-206-02 was carried-out on the finished product IAG-21-001 for the 20mg dosage form. The method repeated six times and the relative standard deviation (RSD) was calculated.SAMPLENumber%ASSAYof labeled amountI 96.9II 97.8III 98.2IV 97.4V 97.7VI 98.5(%) Average97.7SD 0.6(%) RSD0.6PRECISION - Intermediate PrecisionThe full method as described in SI-IAG-206-02 was carried-out on the finished product IAG-21-001 for the 20mg dosage form. The method was repeated six times by a second analyst on a different day using a different HPLC instrument. The average assay and the relative standard deviation (RSD) were calculated.SAMPLENumber% ASSAYof labeled amountI 98.3II 96.3III 94.6IV 96.3V 97.8VI 93.3Average (%)96.1SD 2.0RSD (%)2.1The difference between the average results of method repeatability and the intermediate precision is 1.7%.HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationLINEARITYStandard solutions were prepared at 50% to 200% of the nominal concentration required by the assay procedure. Linear regression analysis demonstrated acceptability of the method for quantitative analysis over the concentration range required. Y-Intercept was found to be insignificant.RANGEDifferent concentrations of the sample (IAG-21-001) for the 20mg dosage form were prepared, covering between 50% - 200% of the nominal weight of the sample.Conc. (%)Conc. (mg/mL)Peak Area% Assayof labeled amount500.20116235096.7700.27935334099.21000.39734463296.61500.64480757797.52000.79448939497.9(%) Average97.6SD 1.0(%) RSD 1.0ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::RANGE (cont.)The results demonstrate linearity as well over the specified range.Correlation coefficient (RSQ)0.99981 Slope11808.3Y -Interceptresponse at 100%* 100 (%) 0.3%ACCURACYACCURACY OF STANDARD INJECTIONSFive (5) replicate injections of the working standard solution at concentration of 0.4242mg/mL, as described in method SI-IAG-206-02 were made.INJECTIONNO.PEAK AREA%ACCURACYI 539299.7II 540599.9III 540499.9IV 5406100.0V 5407100.0Average 5402.899.9%SD 6.10.1RSD, (%)0.10.1The percent deviation from the true value wasdetermined from the linear regression lineHPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::ACCURACY OF THE DRUG PRODUCTAdmixtures of non-actives (placebo, batch IAG-21-001 ) with Fluoxetine HCl were prepared at the same proportion as in a capsule (70%-180% of the nominal concentration).Three preparations were made for each concentration and the recovery was calculated.Conc.(%)Placebo Wt.(mg)Fluoxetine HCl Wt.(mg)Peak Area%Accuracy Average (%)70%7079.477.843465102.27079.687.873427100.77079.618.013465100.0101.0100%10079.6211.25476397.910080.8011.42491799.610079.6011.42485498.398.6130%13079.7214.90640599.413080.3114.75632899.213081.3314.766402100.399.618079.9920.10863699.318079.3820.45879499.418080.0820.32874899.599.4Placebo, Batch Lot IAG-21-001HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::VALIDATION OF FLUOXETINE HClAT LOW CONCENTRATIONLINEARITY AT LOW CONCENTRATIONSStandard solution of Fluoxetine were prepared at approximately 0.02%-1.0% of the working concentration required by the method SI-IAG-206-02. Linear regression analysis demonstrated acceptability of the method for quantitative analysis over this range.ACCURACY OF FLUOXETINE HCl AT LOW CONCENTRATIONThe peak areas of the standard solution at the working concentration were measured and the percent deviation from the true value, as determined from the linear regression was calculated.SAMPLECONC.µg/100mLAREA FOUND%ACCURACYI 470.56258499.7II 470.56359098.1III 470.561585101.3IV 470.561940100.7V 470.56252599.8VI 470.56271599.5(%) AverageSlope = 132.7395299.9SD Y-Intercept = -65.872371.1(%) RSD1.1HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSystem RepeatabilitySix replicate injections of standard solution at 0.02% and 0.05% of working concentration as described in method SI-IAG-206-02 were made and the relative standard deviation was calculated.SAMPLE FLUOXETINE HCl AREA0.02%0.05%I10173623II11503731III10103475IV10623390V10393315VI10953235Average10623462RSD, (%) 5.0 5.4Quantitation Limit - QLThe quantitation limit ( QL) was established by determining the minimum level at which the analyte was quantified. The quantitation limit for Fluoxetine HCl is 0.02% of the working standard concentration with resulting RSD (for six injections) of 5.0%. Detection Limit - DLThe detection limit (DL) was established by determining the minimum level at which the analyte was reliably detected. The detection limit of Fluoxetine HCl is about 0.01% of the working standard concentration.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::VALIDATION FOR META-FLUOXETINE HCl(EVALUATING POSSIBLE IMPURITIES)Meta-Fluoxetine HCl linearity at 0.05% - 1.0%Relative Response Factor (F)Relative response factor for Meta-Fluoxetine HCl was determined as slope of Fluoxetine HCl divided by the slope of Meta-Fluoxetine HCl from the linearity graphs (analysed at the same time).F =132.7395274.859534= 1.8Detection Limit (DL) for Fluoxetine HClThe detection limit (DL) was established by determining the minimum level at which the analyte was reliably detected.Detection limit for Meta Fluoxetine HCl is about 0.02%.Quantitation Limit (QL) for Meta-Fluoxetine HClThe QL is determined by the analysis of samples with known concentration of Meta-Fluoxetine HCl and by establishing the minimum level at which the Meta-Fluoxetine HCl can be quantified with acceptable accuracy and precision.Six individual preparations of standard and placebo spiked with Meta-Fluoxetine HCl solution to give solution with 0.05% of Meta Fluoxetine HCl, were injected into the HPLC and the recovery was calculated.HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::META-FLUOXETINE HCl[RECOVERY IN SPIKED SAMPLES].Approx.Conc.(%)Known Conc.(µg/100ml)Area in SpikedSampleFound Conc.(µg/100mL)Recovery (%)0.0521.783326125.735118.10.0521.783326825.821118.50.0521.783292021.55799.00.0521.783324125.490117.00.0521.783287220.96996.30.0521.783328526.030119.5(%) AVERAGE111.4SD The recovery result of 6 samples is between 80%-120%.10.7(%) RSDQL for Meta Fluoxetine HCl is 0.05%.9.6Accuracy for Meta Fluoxetine HClDetermination of Accuracy for Meta-Fluoxetine HCl impurity was assessed using triplicate samples (of the drug product) spiked with known quantities of Meta Fluoxetine HCl impurity at three concentrations levels (namely 80%, 100% and 120% of the specified limit - 0.05%).The results are within specifications:For 0.4% and 0.5% recovery of 85% -115%For 0.6% recovery of 90%-110%HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::META-FLUOXETINE HCl[RECOVERY IN SPIKED SAMPLES]Approx.Conc.(%)Known Conc.(µg/100mL)Area in spikedSample Found Conc.(µg/100mL)Recovery (%)[0.4%]0.4174.2614283182.66104.820.4174.2614606187.11107.370.4174.2614351183.59105.36[0.5%]0.5217.8317344224.85103.220.5217.8316713216.1599.230.5217.8317341224.81103.20[0.6%]0.6261.3918367238.9591.420.6261.3920606269.81103.220.6261.3920237264.73101.28RECOVERY DATA DETERMINED IN SPIKED SAMPLESHPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::REPEATABILITYMethod Repeatability - Meta Fluoxetine HClThe full method (as described in SI-IAG-206-02) was carried out on the finished drug product representing lot number IAG-21-001-(1). The HPLC method repeated serially, six times and the relative standard deviation (RSD) was calculated.IAG-21-001 20mg CAPSULES - FLUOXETINESample% Meta Fluoxetine % Meta-Fluoxetine 1 in Spiked Solution10.0260.09520.0270.08630.0320.07740.0300.07450.0240.09060.0280.063AVERAGE (%)0.0280.081SD 0.0030.012RSD, (%)10.314.51NOTE :All results are less than QL (0.05%) therefore spiked samples with 0.05% Meta Fluoxetine HCl were injected.HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::Intermediate Precision - Meta-Fluoxetine HClThe full method as described in SI-IAG-206-02 was applied on the finished product IAG-21-001-(1) .It was repeated six times, with a different analyst on a different day using a different HPLC instrument.The difference between the average results obtained by the method repeatability and the intermediate precision was less than 30.0%, (11.4% for Meta-Fluoxetine HCl as is and 28.5% for spiked solution).IAG-21-001 20mg - CAPSULES FLUOXETINESample N o:Percentage Meta-fluoxetine% Meta-fluoxetine 1 in spiked solution10.0260.06920.0270.05730.0120.06140.0210.05850.0360.05560.0270.079(%) AVERAGE0.0250.063SD 0.0080.009(%) RSD31.514.51NOTE:All results obtained were well below the QL (0.05%) thus spiked samples slightly greater than 0.05% Meta-Fluoxetine HCl were injected. The RSD at the QL of the spiked solution was 14.5%HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSPECIFICITY - STABILITY INDICATING EVALUATIONDemonstration of the Stability Indicating parameters of the HPLC assay method [SI-IAG-206-02] for Fluoxetine 10 & 20mg capsules, a suitable photo-diode array detector was incorporated utilizing a commercial chromatography software managing system2, and applied to analyze a range of stressed samples of the finished drug product.GLOSSARY of PEAK PURITY RESULT NOTATION (as reported2):Purity Angle-is a measure of spectral non-homogeneity across a peak, i.e. the weighed average of all spectral contrast angles calculated by comparing all spectra in the integrated peak against the peak apex spectrum.Purity Threshold-is the sum of noise angle3 and solvent angle4. It is the limit of detection of shape differences between two spectra.Match Angle-is a comparison of the spectrum at the peak apex against a library spectrum.Match Threshold-is the sum of the match noise angle3 and match solvent angle4.3Noise Angle-is a measure of spectral non-homogeneity caused by system noise.4Solvent Angle-is a measure of spectral non-homogeneity caused by solvent composition.OVERVIEWT he assay of the main peak in each stressed solution is calculated according to the assay method SI-IAG-206-02, against the Standard Solution, injected on the same day.I f the Purity Angle is smaller than the Purity Threshold and the Match Angle is smaller than the Match Threshold, no significant differences between spectra can be detected. As a result no spectroscopic evidence for co-elution is evident and the peak is considered to be pure.T he stressed condition study indicated that the Fluoxetine peak is free from any appreciable degradation interference under the stressed conditions tested. Observed degradation products peaks were well separated from the main peak.1® PDA-996 Waters™ ; 2[Millennium 2010]ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationFORCED DEGRADATION OF FINISHED PRODUCT & STANDARD 1.UNSTRESSED SAMPLE1.1.Sample IAG-21-001 (2) (20mg/capsule) was prepared as stated in SI-IAG-206-02 and injected into the HPLC system. The calculated assay is 98.5%.SAMPLE - UNSTRESSEDFluoxetine:Purity Angle:0.075Match Angle:0.407Purity Threshold:0.142Match Threshold:0.4251.2.Standard solution was prepared as stated in method SI-IAG-206-02 and injected into the HPLC system. The calculated assay is 100.0%.Fluoxetine:Purity Angle:0.078Match Angle:0.379Purity Threshold:0.146Match Threshold:0.4272.ACID HYDROLYSIS2.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as in method SI-IAG-206-02 : An amount equivalent to 20mg Fluoxetine was weighed into a 50mL volumetric flask. 20mL Diluent was added and the solution sonicated for 10 minutes. 1mL of conc. HCl was added to this solution The solution was allowed to stand for 18 hours, then adjusted to about pH = 5.5 with NaOH 10N, made up to volume with Diluent and injected into the HPLC system after filtration.Fluoxetine peak intensity did NOT decrease. Assay result obtained - 98.8%.SAMPLE- ACID HYDROLYSISFluoxetine peak:Purity Angle:0.055Match Angle:0.143Purity Threshold:0.096Match Threshold:0.3712.2.Standard solution was prepared as in method SI-IAG-206-02 : about 22mg Fluoxetine HCl were weighed into a 50mL volumetric flask. 20mL Diluent were added. 2mL of conc. HCl were added to this solution. The solution was allowed to stand for 18 hours, then adjusted to about pH = 5.5 with NaOH 10N, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity did NOT decrease. Assay result obtained - 97.2%.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSTANDARD - ACID HYDROLYSISFluoxetine peak:Purity Angle:0.060Match Angle:0.060Purity Threshold:0.099Match Threshold:0.3713.BASE HYDROLYSIS3.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as per method SI-IAG-206-02 : An amount equivalent to 20mg Fluoxetine was weight into a 50mL volumetric flask. 20mL Diluent was added and the solution sonicated for 10 minutes. 1mL of 5N NaOH was added to this solution. The solution was allowed to stand for 18 hours, then adjusted to about pH = 5.5 with 5N HCl, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity did NOT decrease. Assay result obtained - 99.3%.SAMPLE - BASE HYDROLYSISFluoxetine peak:Purity Angle:0.063Match Angle:0.065Purity Threshold:0.099Match Threshold:0.3623.2.Standard stock solution was prepared as per method SI-IAG-206-02 : About 22mg Fluoxetine HCl was weighed into a 50mL volumetric flask. 20mL Diluent was added. 2mL of 5N NaOH was added to this solution. The solution was allowed to stand for 18 hours, then adjusted to about pH=5.5 with 5N HCl, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity did NOT decrease - 99.5%.STANDARD - BASE HYDROLYSISFluoxetine peak:Purity Angle:0.081Match Angle:0.096Purity Threshold:0.103Match Threshold:0.3634.OXIDATION4.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as per method SI-IAG-206-02. An equivalent to 20mg Fluoxetine was weighed into a 50mL volumetric flask. 20mL Diluent added and the solution sonicated for 10 minutes.1.0mL of 30% H2O2 was added to the solution and allowed to stand for 5 hours, then made up to volume with Diluent, filtered and injected into HPLC system.Fluoxetine peak intensity decreased to 95.2%.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSAMPLE - OXIDATIONFluoxetine peak:Purity Angle:0.090Match Angle:0.400Purity Threshold:0.154Match Threshold:0.4294.2.Standard solution was prepared as in method SI-IAG-206-02 : about 22mg Fluoxetine HCl were weighed into a 50mL volumetric flask and 25mL Diluent were added. 2mL of 30% H2O2 were added to this solution which was standing for 5 hours, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity decreased to 95.8%.STANDARD - OXIDATIONFluoxetine peak:Purity Angle:0.083Match Angle:0.416Purity Threshold:0.153Match Threshold:0.4295.SUNLIGHT5.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as in method SI-IAG-206-02 . The solution was exposed to 500w/hr. cell sunlight for 1hour. The BST was set to 35°C and the ACT was 45°C. The vials were placed in a horizontal position (4mm vials, National + Septum were used). A Dark control solution was tested. A 2%w/v quinine solution was used as the reference absorbance solution.Fluoxetine peak decreased to 91.2% and the dark control solution showed assay of 97.0%. The difference in the absorbance in the quinine solution is 0.4227AU.Additional peak was observed at RRT of 1.5 (2.7%).The total percent of Fluoxetine peak with the degradation peak is about 93.9%.SAMPLE - SUNLIGHTFluoxetine peak:Purity Angle:0.093Match Angle:0.583Purity Threshold:0.148Match Threshold:0.825 ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSUNLIGHT (Cont.)5.2.Working standard solution was prepared as in method SI-IAG-206-02 . The solution was exposed to 500w/hr. cell sunlight for 1.5 hour. The BST was set to 35°C and the ACT was 42°C. The vials were placed in a horizontal position (4mm vials, National + Septum were used). A Dark control solution was tested. A 2%w/v quinine solution was used as the reference absorbance solution.Fluoxetine peak was decreased to 95.2% and the dark control solution showed assay of 99.5%.The difference in the absorbance in the quinine solution is 0.4227AU.Additional peak were observed at RRT of 1.5 (2.3).The total percent of Fluoxetine peak with the degradation peak is about 97.5%. STANDARD - SUNLIGHTFluoxetine peak:Purity Angle:0.067Match Angle:0.389Purity Threshold:0.134Match Threshold:0.8196.HEAT OF SOLUTION6.1.Sample solution of IAG-21-001-(2) (20 mg/capsule) was prepared as in method SI-IAG-206-02 . Equivalent to 20mg Fluoxetine was weighed into a 50mL volumetric flask. 20mL Diluent was added and the solution was sonicated for 10 minutes and made up to volume with Diluent. 4mL solution was transferred into a suitable crucible, heated at 105°C in an oven for 2 hours. The sample was cooled to ambient temperature, filtered and injected into the HPLC system.Fluoxetine peak was decreased to 93.3%.SAMPLE - HEAT OF SOLUTION [105o C]Fluoxetine peak:Purity Angle:0.062Match Angle:0.460Purity Threshold:0.131Match Threshold:0.8186.2.Standard Working Solution (WS) was prepared under method SI-IAG-206-02 . 4mL of the working solution was transferred into a suitable crucible, placed in an oven at 105°C for 2 hours, cooled to ambient temperature and injected into the HPLC system.Fluoxetine peak intensity did not decrease - 100.5%.ED. N0: 04Effective Date:APPROVED::。
美国贝克曼库尔特流式细胞分析仪
美国贝克曼库尔特流式细胞分析仪（Beckman coulter cell）产品型号：Cell Lab Quanta SC当前价格：0.00元产品数量：0新旧程度：全新有效期至：0000-00-00所在地：产品简介：仪器简介：T细胞亚群检测的CD45/CD4/CD8/CD3、CD45/CD56/CD19/CD3；阵发性血红蛋白尿（PNH）检测的CD55、CD59；血小板无力症（GT）检测的CD41、CD61等等详细信息仪器简介：T细胞亚群检测的CD45/CD4/CD8/CD3、CD45/CD56/CD19/CD3；阵发性血红蛋白尿（PNH）检测的CD55、CD59；血小板无力症（GT）检测的CD41、CD61等等。
但对于白血病/淋巴瘤免疫分型，国际上迄今为止也没有统一的抗体组合。
在2000年国际细胞分析学会（ISAC）大会上，临床血细胞计数协会组织了一次国际专家会议，以期对检测血液淋巴系统肿瘤所需最少、最有效的单抗数达成共识。
75%与会者一致认为，对于慢性淋巴系统增殖性疾病（CLD）有9种单抗：CD5,CD19,κ,λ,CD3,CD20,CD23,CD10,CD45对初诊来说是最基本的。
淋巴瘤和CLD相似，需要至少12-16种单抗。
对于急性白血病（AL），75%的与会者认为大约13-15种单抗是最基本的：CD10,CD19,CD79a,CD13,CD33,CD34,CD45,CD2,MPO，CD7,CD14,CD3,HLA-DR等，对初步鉴别白血病系列是必需的。
其他一些（CD16,CD56,CDw65,TdT,cyCD3）可能对某些病例有用。
几乎所有的投票者都认为，要对急性白血病完善分类所需单抗的恰当数量平均为20-24种。
但这些抗体之间组合也是一大难题，目前也无统一规定（如表二）。
大会多数发言者(11/13)指出，对已确诊病人的监护和分期来说，仅需较少单抗。
抗体的质量控制是实验的关键环节。
抗体的质量包括其特异性、灵敏度、精密度。
Elabscience
（本试剂盒仅供体外研究使用，不用于临床诊断！）Elabscience®活性氧(ROS)荧光法测试盒Reactive Oxygen Species (ROS)Fluorometric Assay Kit产品货号：E-BC-K138-F产品规格：96T检测仪器：荧光酶标仪(激发波长485-515 nm，发射波长510-550 nm) 使用前请仔细阅读说明书。
如果有任何问题，请通过以下方式联系我们：销售部电话************，************技术部电话131****6790具体保质期请见试剂盒外包装标签。
请在保质期内使用试剂盒。
联系时请提供产品批号(见试剂盒标签)，以便我们更高效地为您服务。
用途本试剂盒适用于检测组织细胞，培养细胞中的活性氧。
检测原理DCFH-DA（2,7-dichlorofuorescin diacetate）是一种可以自由穿过细胞膜的荧光探针，自身没有荧光，进入细胞内后，可以被细胞内的酯酶水解生成DCFH（dichlorofluorescin）。
在活性氧存在时DCFH被氧化为不能透过细胞膜的强绿色荧光物质DCF（dichlorofluorescein），其荧光在激发波长502 nm，发射波长530 nm附近有最大波峰，强度与细胞内活性氧水平成正比。
提供试剂和物品说明：试剂严格按上表中的保存条件保存，不同测试盒中的试剂不能混用。
对于体积较少的试剂，使用前请先离心，以免量取不到足够量的试剂。
所需自备物品仪器：荧光酶标仪（Ex/Em=500 nm/525 nm）、流式细胞仪或荧光显微镜试剂：双蒸水、PBS（0.01 M，pH 7.4）、无血清细胞培养液试剂准备①试剂一工作液的配制：将试剂一用无血清细胞培养液稀释，现配现用。
推荐初始工作浓度为10 μM，对于不同的样本和处理，试剂一工作液浓度可为0.1-20 μM，需进行预实验确定合适的浓度。
总体稀释倍数应在1:500-1:1000以上以避免DMSO对细胞的影响②试剂一工作液的使用：加入试剂一工作液的时机或孵育时间，以最终能顺利检测细胞内活性氧为目的。